Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 15/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 14/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 14/20 | 1.00 |
| ▸ | ACVRL1 | P37023 | 14/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 4/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 4/20 | 1.00 |
| ▸ | BMPR2 | Q13873 | 4/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 1.00 |
| ▸ | BMP4 | P12644 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ACVR2A | P27037 | 1/20 | 1.00 |
| ▸ | ACVR2B | Q13705 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353046 | 1.00 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL22462135 | 0.99 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL29634729 | 0.99 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL2059683 | 0.99 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL29373122 | 0.99 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hypochlorous Acid SCHEMBL26968209 | 0.97 | ACVR1B (0.94) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL24908393 | 0.94 | ACVR1B (0.89) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL29391702 | 0.93 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL16025991 | 0.93 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL30388107 | 0.92 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4079314-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4070803-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3047017-B1 | METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2024210619-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | 재단법인 아산사회복지재단 | 2024-10-10 | — | — | WO | claimed |
| US-12084679-B2 | Methods of in vitro differentiation of midbrain dopamine (mDA) neurons | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024079755-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | claimed |
| WO-2024052931-A1 | A PROTOCOL FOR GENERATING NEURAL PROGENITOR CELLS AND IMPLEMENTATIONS THEREOF | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-03-14 | — | — | WO | claimed |
| US-20230323294-A1 | DIFFERENTIATION OF CORTICAL NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | claimed |
| EP-4079314-A1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | Memorial Sloan-Kettering Cancer Center (US) | 2022-10-26 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| WO-2015087231-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | PFIZER LIMITED (GB) | 2015-06-18 | — | — | WO | claimed |
| US-20150159134-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | PFIZER LIMITED (GB) | 2015-06-11 | — | — | US | claimed |
| WO-2015061568-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | claimed |
| US-20120142093-A1 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO NEURAL PRECURSOR CELLS | KYOTO UNIVERSITY (JP) | 2012-06-07 | — | — | US | claimed |
| WO-2012034101-A2 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159134-A1 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, ALDH1A3, EYA3 | ACVR1 3649/4885ACVR1B 3755/4885BMPR1A 3681/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | ACVR1 514/4885ACVR1B 607/4885BMPR1A 1236/4885 |
| US-12084679-B2 | Methods of in vitro differentiation of midbrain dopamine (mDA) neurons | CHAT, DCX, DBH | ACVR1 4249/4885ACVR1B 3509/4885BMPR1A 3573/4885 |
| US-20230323294-A1 | DIFFERENTIATION OF CORTICAL NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | CHAT, DCX, NES | ACVR1 3778/4885ACVR1B 3162/4885BMPR1A 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.